We are upgrading the repository! A content freeze is in effect until December 11, 2024. New submissions or changes to existing items will not be allowed during this period. All content already published will remain publicly available for searching and downloading. Updates will be posted in the Website Upgrade 2024 FAQ in the sidebar Help menu. Reach out to escholarship@umassmed.edu with any questions.

Show simple item record

dc.contributor.authorEvens, Andrew M.
dc.contributor.authorAdvani, Ranjana
dc.contributor.authorPress, Oliver W.
dc.contributor.authorLossos, Izidore S.
dc.contributor.authorVose, Julie M.
dc.contributor.authorHernandez-Ilizaliturri, Francisco J.
dc.contributor.authorRobinson, Barrett K.
dc.contributor.authorOtis, Stavroula
dc.contributor.authorNadav Dagan, Liat
dc.contributor.authorAbdallah, Ramsey
dc.contributor.authorKroll-Desrosiers, Aimee
dc.date2022-08-11T08:08:33.000
dc.date.accessioned2022-08-23T15:58:52Z
dc.date.available2022-08-23T15:58:52Z
dc.date.issued2013-11-10
dc.date.submitted2015-11-25
dc.identifier.citationJ Clin Oncol. 2013 Nov 10;31(32):4132-9. doi: 10.1200/JCO.2013.49.8220. Epub 2013 Sep 16. <a href="http://dx.doi.org/10.1200/JCO.2013.49.8220">Link to article on publisher's site</a>
dc.identifier.issn0732-183X (Linking)
dc.identifier.doi10.1200/JCO.2013.49.8220
dc.identifier.pmid24043736
dc.identifier.urihttp://hdl.handle.net/20.500.14038/30532
dc.description<p>Co-author Aimee Kroll-Desrosiers is a doctoral student in the Clinical and Population Health Research Program in the Graduate School of Biomedical Sciences (GSBS) at UMass Medical School.</p> <p>Full author list omitted for brevity. For the full list of authors, see article.</p>
dc.description.abstractPURPOSE: Lymphoma is the fourth most frequent cancer in pregnancy; however, current clinical practice is based largely on small series and case reports. PATIENTS AND METHODS: In a multicenter retrospective analysis, we examined treatment, complications, and outcomes for Hodgkin lymphoma (HL) and non-Hodgkin lymphoma (NHL) occurring during pregnancy. RESULTS: Among 90 patients (NHL, n = 50; HL, n = 40), median age was 30 years (range, 18 to 44 years) and median diagnosis occurred at 24 weeks gestation. Of patients with NHL, 52% had advanced-stage versus 25% of patients with HL (P = .01). Pregnancy was terminated in six patients. Among the other 84 patients, 28 (33%) had therapy deferred to postpartum; these patients were diagnosed at a median 30 weeks gestation. This compared with 56 patients (67%) who received antenatal therapy with median lymphoma diagnosis at 21 weeks (P < .001); 89% of these patients received combination chemotherapy. The most common preterm complication was induction of labor (33%). Gestation went to full term in 56% of patients with delivery occurring at a median of 37 weeks. There were no differences in maternal complications, perinatal events, or median infant birth weight based on deferred versus antenatal therapy. At 41 months, 3-year progression-free survival (PFS) and overall survival (OS) for NHL were 53% and 82%, respectively, and 85% and 97%, respectively, for HL. On univariate analysis for NHL, radiotherapy predicted inferior PFS, and increased lactate dehydrogenase and poor Eastern Cooperative Oncology Group performance status (ECOG PS) portended worse OS. For HL patients, nulliparous status and "B" symptoms predicted inferior PFS. CONCLUSION: Standard (non-antimetabolite) combination chemotherapy administered past the first trimester, as early as 13 weeks gestation, was associated with few complications and expected maternal survival with lymphoma occurring during pregnancy.
dc.language.isoen_US
dc.relation<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=pubmed&cmd=Retrieve&list_uids=24043736&dopt=Abstract">Link to Article in PubMed</a>
dc.relation.urlhttp://dx.doi.org/10.1200/JCO.2013.49.8220
dc.subjectAdolescent
dc.subjectAdult
dc.subjectAntineoplastic Combined Chemotherapy Protocols
dc.subjecteffects
dc.subjectDisease-Free Survival
dc.subjectFemale
dc.subjectFetus
dc.subjectHumans
dc.subjectKaplan-Meier Estimate
dc.subjectLymphoma
dc.subjectPregnancy
dc.subjectPregnancy Complications, Neoplastic
dc.subject*Pregnancy Outcome
dc.subjectRetrospective Studies
dc.subjectTreatment Outcome
dc.subjectYoung Adult
dc.subjectFemale Urogenital Diseases and Pregnancy Complications
dc.subjectMaternal and Child Health
dc.subjectNeoplasms
dc.subjectObstetrics and Gynecology
dc.subjectOncology
dc.subjectWomen's Health
dc.titleLymphoma occurring during pregnancy: antenatal therapy, complications, and maternal survival in a multicenter analysis
dc.typeJournal Article
dc.source.journaltitleJournal of clinical oncology : official journal of the American Society of Clinical Oncology
dc.source.volume31
dc.source.issue32
dc.identifier.legacycoverpagehttps://escholarship.umassmed.edu/faculty_pubs/808
dc.identifier.contextkey7880383
html.description.abstract<p>PURPOSE: Lymphoma is the fourth most frequent cancer in pregnancy; however, current clinical practice is based largely on small series and case reports.</p> <p>PATIENTS AND METHODS: In a multicenter retrospective analysis, we examined treatment, complications, and outcomes for Hodgkin lymphoma (HL) and non-Hodgkin lymphoma (NHL) occurring during pregnancy.</p> <p>RESULTS: Among 90 patients (NHL, n = 50; HL, n = 40), median age was 30 years (range, 18 to 44 years) and median diagnosis occurred at 24 weeks gestation. Of patients with NHL, 52% had advanced-stage versus 25% of patients with HL (P = .01). Pregnancy was terminated in six patients. Among the other 84 patients, 28 (33%) had therapy deferred to postpartum; these patients were diagnosed at a median 30 weeks gestation. This compared with 56 patients (67%) who received antenatal therapy with median lymphoma diagnosis at 21 weeks (P < .001); 89% of these patients received combination chemotherapy. The most common preterm complication was induction of labor (33%). Gestation went to full term in 56% of patients with delivery occurring at a median of 37 weeks. There were no differences in maternal complications, perinatal events, or median infant birth weight based on deferred versus antenatal therapy. At 41 months, 3-year progression-free survival (PFS) and overall survival (OS) for NHL were 53% and 82%, respectively, and 85% and 97%, respectively, for HL. On univariate analysis for NHL, radiotherapy predicted inferior PFS, and increased lactate dehydrogenase and poor Eastern Cooperative Oncology Group performance status (ECOG PS) portended worse OS. For HL patients, nulliparous status and "B" symptoms predicted inferior PFS.</p> <p>CONCLUSION: Standard (non-antimetabolite) combination chemotherapy administered past the first trimester, as early as 13 weeks gestation, was associated with few complications and expected maternal survival with lymphoma occurring during pregnancy.</p>
dc.identifier.submissionpathfaculty_pubs/808
dc.contributor.departmentDepartment of Quantitative Health Sciences
dc.source.pages4132-9


This item appears in the following Collection(s)

Show simple item record